The downstream pathways regulated by the core metabolite were identified by RNA-seq and validated by Western Blot assays and immunofluorescence. Then potential targets were further validated in ...

Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression.

The complex interplay between different components of the MAPK pathway, including KRAS, BRAF, CRAF, their regulators, and downstream effectors, has led to new insights into resistance mechanisms and ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF ... models corresponding with nearly complete shutdown of RAS/MAPK pathway signaling BOSTON, March 25, 2025--(BUSINESS WIRE)--Verastem ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

When one of the proteins in the pathway is mutationally activated, it can drive tumor development and growth. RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring ...

Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven ... 7375 (GFH375), an oral KRAS G12D (ON/OFF) inhibitor ...